Fundación Gecp

This Phase III trial tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery can delay or prevent the cancer from coming back. It enrolls 210 patients with stage IB-IIIA non-small cell lung cancer that was completely removed. Participants are randoml…

This phase 2 trial tests giving chemotherapy (carboplatin and paclitaxel) plus the immunotherapy drug nivolumab before surgery for people with Pancoast tumors, a rare type of lung cancer. After surgery, additional treatment is tailored based on whether the tumor was fully removed…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This phase II trial tests whether adding immunotherapy to standard chemotherapy before surgery helps eliminate more lung cancer in patients with advanced, but potentially removable, non-small cell lung cancer. 90 participants will be randomly assigned to receive either chemo-immu…

This phase II trial is testing whether adding two targeted drugs (pembrolizumab and lenvatinib) to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer growing. The study involves 46 participants who have not had prior…

This study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a certain type of advanced lung cancer (ALK-positive NSCLC). About 33 patients who have not had chemotherapy before will take brigatinib pills dail…

This study is looking at 100 people with stage IIIA lung cancer who are getting treatment before surgery. Researchers want to see if a blood test that looks for tumor DNA (ctDNA) can predict how well patients do. If the tumor DNA disappears after treatment, it might mean a better…